Decoy Therapeutics Partners With HVIVO to Advance D-MAV Into Clinical Study, Stock Rises

Decoy Therapeutics announced on June 1, 2026, that it has partnered with clinical research organization HVIVO to advance its lead drug candidate D-MAV into a clinical study, sending its shares higher. The biopharmaceutical company did not disclose financial terms of the agreement. Shares of Decoy rose following the news, though exact percentage gains were not immediately reported. D-MAV is Decoy’s most advanced program, targeting an undisclosed indication. The partnership marks a key milestone as the company moves toward human trials.